| Year |
Citation |
Score |
| 2020 |
Poulin Y, Beauchemin C, Royer C, Gaudreau AJ, Yim C, Liu FF, Lachaine J. Real-World Experience with Apremilast in the Treatment of Adults with Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization. Journal of Cutaneous Medicine and Surgery. 1203475420936652. PMID 32597685 DOI: 10.1177/1203475420936652 |
0.34 |
|
| 2019 |
Lachaine J, Ben Amor L, Pringsheim T, Burns J, van Stralen J. Treatment Patterns, Health Care Resource Utilization, and Health Care Cost Associated with Atypical Antipsychotics or Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Quebec, Canada. Journal of Child and Adolescent Psychopharmacology. PMID 31433205 DOI: 10.1089/Cap.2019.0097 |
0.348 |
|
| 2019 |
Mathurin K, Beauchemin C, Lachaine J, Gaudet V, Barbeau M. PIN33 COST-EFFECTIVENESS ANALYSIS OF EFINACONAZOLE FOR THE TREATMENT OF MILD TO MODERATE TOENAIL ONYCHOMYCOSIS IN CANADA Value in Health. 22: S199. DOI: 10.1016/J.Jval.2019.04.904 |
0.358 |
|
| 2018 |
Stip E, Lachaine J. Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec. Therapeutic Advances in Psychopharmacology. 8: 287-301. PMID 30344996 DOI: 10.1177/2045125318782694 |
0.325 |
|
| 2018 |
Lambert-Obry V, Gouault-Laliberté A, Castonguay A, Zanotti G, Tran T, Mates M, Lemieux J, Chabot P, Prady C, Couture F, Lachaine J. Real-world patient- and caregiver-reported outcomes in advanced breast cancer. Current Oncology (Toronto, Ont.). 25: e282-e290. PMID 30111973 DOI: 10.3747/Co.25.3765 |
0.303 |
|
| 2016 |
Beauchemin C, Lapierre MÈ, Letarte N, Yelle L, Lachaine J. Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available. Pharmacoeconomics. PMID 27002517 DOI: 10.1007/S40273-016-0401-4 |
0.313 |
|
| 2016 |
Beauchemin C, Letarte N, Mathurin K, Yelle L, Lachaine J. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada. Journal of Medical Economics. 19: 619-29. PMID 26850287 DOI: 10.3111/13696998.2016.1151431 |
0.382 |
|
| 2016 |
Lachance S, Bibeau J, Lachaine J. Burden of Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation on Health Care Resource Utilization in the Management of Acute Leukemia and Myelodysplastic Syndrome Blood. 128: 2372-2372. DOI: 10.1182/Blood.V128.22.2372.2372 |
0.327 |
|
| 2016 |
Lambert-Obry V, Gouault-Laliberté A, Castonguay A, Aubin M, Vadboncoeur J, Laliberté M, Lachaine J. Health Care Resource Utilization and Costs Associated with the Management of Non-Infectious Intermediate, Posterior and Panuveitis in Canada Value in Health. 19: A614. DOI: 10.1016/J.Jval.2016.09.1539 |
0.322 |
|
| 2016 |
Beauchemin C, Letarte N, Mathurin K, Yelle L, Lachaine J. A Global Economic Model to Assess the Cost Effectiveness of New Treatments for Advanced Breast Cancer in Canada Value in Health. 19: A151. DOI: 10.1016/J.Jval.2016.03.1598 |
0.327 |
|
| 2016 |
Lachaine J, Kouroukis C. ECONOMIC EVALUATION OF BENDAMUSTINE PLUS RITUXIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA Value in Health. 19: A248. DOI: 10.1016/J.Jval.2016.03.1063 |
0.304 |
|
| 2015 |
Lachaine J, Mathurin K, Barakat S, Schuh AC. Economic evaluation of arsenic trioxide for treatment of newly diagnosed acute promyelocytic leukaemia in Canada. Hematological Oncology. 33: 229-38. PMID 25424534 DOI: 10.1002/Hon.2176 |
0.387 |
|
| 2015 |
Lachaine J, Mathurin K, Barakat S, Couban S. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada. European Journal of Haematology. 95: 218-29. PMID 25354894 DOI: 10.1111/Ejh.12475 |
0.304 |
|
| 2015 |
Beauchemin C, Lapierre M, Letarte N, Yelle L, Lachaine J. How To Conduct Economic Evaluations Of New Treatments For Advanced Cancer When Overall Survival Data Are Not Available? Results From A Systematic Literature Review Value in Health. 18: A682. DOI: 10.1016/J.Jval.2015.09.2518 |
0.307 |
|
| 2015 |
Ãgh T, Pawaskar M, Voko Z, Nagy B, Lachaine J. The Cost-Effectiveness of Lisdexamfetamine Dimesylate for The Treatment of Binge Eating Disorder Value in Health. 18: A284. DOI: 10.1016/J.Jval.2015.03.1656 |
0.318 |
|
| 2014 |
Mathurin K, Beauchemin C, Lachaine J. Development Of A Global Economic Model To Evaluate The Cost-Effectiveness Of Targeted Treatments Using Companion Diagnostics In Advanced/Metastatic Cancer Treatment. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 17: A561. PMID 27201855 DOI: 10.1016/J.Jval.2014.08.1855 |
0.349 |
|
| 2014 |
Mathurin K, Beauchemin C, Lachaine J. Validation of A Global Economic Model to Evaluate The Cost-Effectiveness Of Targeted Treatments Using Companion Diagnostics In Advanced/Metastatic Cancer Treatment Using Kras Testing For Cetuximab Therapy In Metastatic Colorectal Cancer. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 17: A559. PMID 27201840 DOI: 10.1016/J.Jval.2014.08.1845 |
0.322 |
|
| 2014 |
Lachaine J, Beauchemin C, Mathurin K, Gilbert D, Beillat M. Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada. Journal of Medical Economics. 17: 296-304. PMID 24564402 DOI: 10.3111/13696998.2014.897627 |
0.309 |
|
| 2014 |
Lachaine J, Beauchemin C, Mathurin K, Gilbert D, Beillat M. Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada. Bmc Psychiatry. 14: 16. PMID 24450548 DOI: 10.1186/1471-244X-14-16 |
0.382 |
|
| 2014 |
Touchon J, Lachaine J, Beauchemin C, Granghaud A, Rive B, Bineau S. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France. The European Journal of Health Economics : Hepac : Health Economics in Prevention and Care. 15: 791-800. PMID 23928827 DOI: 10.1007/S10198-013-0523-Y |
0.354 |
|
| 2014 |
Lachaine J, Mathurin K, Barakat S. Cost-Effectiveness of Arsenic Trioxide in the Treatment of Relapsed/Refractory Acute Promyelocytic Lymphoma LEUKEMIA in Canada Value in Health. 17: A84. DOI: 10.1016/J.Jval.2014.03.492 |
0.322 |
|
| 2014 |
Lachaine J, Lapierre M, Abdalla N, Rouleau A, Stip E. Resource use and associated costs of long acting injectable antipsychotics: A RAMQ database analysis Value in Health. 17: A215. DOI: 10.1016/J.Jval.2014.03.1259 |
0.326 |
|
| 2013 |
Lachaine J, Mathurin K, Barakat S. Cost-Effectiveness Of Arsenic Trioxide + All-Trans Retinoic Acid Compared With All-Trans Retinoic Acid + Idarubicin In The Treatment Of Newly Diagnosed Acute Promyelocytic Leukemia In Canada Blood. 122: 1677-1677. DOI: 10.1016/J.Jval.2014.03.486 |
0.352 |
|
| 2013 |
Lachaine J, Baril J, Lambert-Obry V, Beauchemin C. Health Care Resource Utilization and Adherence to Antiretroviral Treatment (ART) by HIV Patients: An Analysis with the Quebec (Canada) Public Drug Plan Database Value in Health. 16: A361. DOI: 10.1016/J.Jval.2013.08.224 |
0.308 |
|
| 2013 |
Mathurin K, Beauchemin C, Lachaine J. The Cost-Effectiveness Of Companion Diagnostics In Cancer Therapy Value in Health. 16: A141. DOI: 10.1016/J.Jval.2013.03.693 |
0.302 |
|
| 2013 |
Lachaine J, Beauchemin C, Mathurin K, Aissa F. Cost-Effectiveness Of Bendamustine+Rituximab Versus Fludarabine+Rituximab In The Treatment Of Relapsed Indolent Non-Hodgkin's And Mantle Cell Lymphomas In Canada Value in Health. 16: A141. DOI: 10.1016/J.Jval.2013.03.690 |
0.32 |
|
| 2012 |
Awissi DK, Bégin C, Moisan J, Lachaine J, Skrobik Y. I-SAVE study: impact of sedation, analgesia, and delirium protocols evaluated in the intensive care unit: an economic evaluation. The Annals of Pharmacotherapy. 46: 21-8. PMID 22202496 DOI: 10.1345/Aph.1Q284 |
0.349 |
|
| 2012 |
Beauchemin C, Cooper D, Lapierre M, Yelle L, Lachaine J. Progression-Free Survival as a Surrogate for Overall Survival in Metastatic Breast Cancer Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)32889-1 |
0.303 |
|
| 2012 |
Lachaine J, Yen L, Beauchemin C, Hodgkins P. PGI10 Factors Associated With Treatment Adherence and Persistence in Canadian Patients With Ulcerative Colitis (Uc): Analysis of Prescription Claims From the Ramq Database Value in Health. 15: A636-A637. DOI: 10.1016/J.Jval.2012.08.2093 |
0.308 |
|
| 2012 |
Lachaine J, Beauchemin C, Koch C, Hurry M, Lacroix A. PDB49 Cost and Health Care Resources Utilization in the Management of Cushing'S Disease: An Analysis Based on the Ramq Database Value in Health. 15: A502. DOI: 10.1016/J.Jval.2012.08.1692 |
0.332 |
|
| 2012 |
Lachaine J, Serri O, Beauchemin C, Hurry M, Koch C. PDB48 Health Care Resources Utilization and Costs Associated With the Management of Patients With Acromegaly: An Analysis Based on the Ramq Database Value in Health. 15: A502. DOI: 10.1016/J.Jval.2012.08.1691 |
0.345 |
|
| 2012 |
Lachaine J, Beauchemin C, Mathurin K, Gilbert D, Beillat M, Corson H. PMH37 Cost-Effectiveness of Asenapine in the Treatment of Bipolar I Disorder in Canada Value in Health. 15: A88. DOI: 10.1016/J.Jval.2012.03.482 |
0.321 |
|
| 2011 |
Lachaine J, Yen L, Beauchemin C, Hodgkins P. PGI23 Economic Impact of Medication Adherence and Persistence in the Treatment of Ulcerative Colitis in Canada: Analyses with the Ramq Database Value in Health. 14: A395-A396. DOI: 10.1016/J.Jval.2011.08.894 |
0.307 |
|
| 2010 |
Beaulieu M, de Denus S, Lachaine J. Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 11: 1573-90. PMID 21121811 DOI: 10.2217/Pgs.10.145 |
0.331 |
|
| 2010 |
Barkun AN, Crott R, Fallone CA, Kennedy WA, Lachaine J, Levinton C, Armstrong D, Chiba N, Thomson A, Veldhuyzen van Zanten S, Sinclair P, Escobedo S, Chakraborty B, Smyth S, White R, et al. A one-year economic evaluation of six alternative strategies in the management of uninvestigated upper gastrointestinal symptoms in Canadian primary care. Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie. 24: 489-98. PMID 20711528 DOI: 10.1155/2010/379583 |
0.356 |
|
| 2010 |
Lachaine J, Beauchemin C, Legault M, Bineau S. PND43 IMPACT OF MEMANTINE TREATMENT INITIATION ON PSYCHOTROPICS USE: ANALYSES WITH THE RAMQ DATABASE Value in Health. 13: A396. DOI: 10.1016/S1098-3015(11)72624-9 |
0.307 |
|
| 2009 |
Roussy JP, Aubin MJ, Brunette I, Lachaine J. Cost of corneal transplantation for the Quebec health care system. Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie. 44: 36-41. PMID 19169311 DOI: 10.3129/I08-180 |
0.317 |
|
| 2009 |
Beauchemin C, Brunette I, Lachaine J. PSS12 COST-UTILITY ANALYSIS OF POSTERIOR LAMELLAR KERATOPLASTY IN CANADA Value in Health. 12: A76-A77. DOI: 10.1016/S1098-3015(10)73444-6 |
0.323 |
|
| 2008 |
Lachaine J, Petrella RJ, Merikle E, Ali F. Choices, persistence and adherence to antihypertensive agents: evidence from RAMQ data. The Canadian Journal of Cardiology. 24: 269-73. PMID 18401466 DOI: 10.1016/S0828-282X(08)70175-2 |
0.321 |
|
| 2008 |
Lachaine J, Hodge WG, Steffensen I, Murray C, Barnes D, Foerster V, Ducruet T, Mensinkai S. Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis. Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie. 43: 33-41. PMID 18219345 DOI: 10.3129/I07-182 |
0.377 |
|
| 2006 |
Lachaine J. Therapeutic options for the prevention and treatment of postoperative nausea and vomiting: a pharmacoeconomic review. Pharmacoeconomics. 24: 955-70. PMID 17002479 DOI: 10.2165/00019053-200624100-00004 |
0.336 |
|
| 2005 |
Lachaine J, Yelle L, Kaizer L, Dufour A, Hopkins S, Deuson R. Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Supportive Cancer Therapy. 2: 181-7. PMID 18628170 DOI: 10.3816/Sct.2005.N.011 |
0.333 |
|
| 2003 |
Lachaine J, Laurier C, Contandriopoulos AP. Defining monetary values for quality of life improvements: an exploratory study. Pharmacoeconomics. 21: 865-74. PMID 12908842 DOI: 10.2165/00019053-200321120-00003 |
0.587 |
|
| 2003 |
Barkun A, Crott R, Fallone C, Kennedy W, Lachaine J, Levinton C, Armstrong D, Chiba N, Thomson A, Veldhuyzen Van Zanten S, Sinclair P, Chakraborty B, Escobedo S, Smyth S, White R, et al. PGS6: THE COST-EFFECTIVENESS OF ALTERNATIVE STRATEGIES IN THE MANAGEMENT OF PATIENTS WITH UNINVESTIGATED DYSPEPSIA (UD): COMPARING THE CANDYS APPROACH TO EMPIRICAL ANTISECRETORY THERAPY AND PROMPT ENDOSCOPY Value in Health. 6: 246-247. DOI: 10.1016/S1098-3015(10)63969-1 |
0.319 |
|
| 2003 |
Barkun AN, Crott R, Fallone C, Kennedy W, Lachaine J, Levington C, Armstrong D, Chiba N, Thomson A, Van Zanten SJ, Sinclair P, Chakraborty B, Escobedo S, Smyth S, White R, et al. THE COST-EFFECTIVENESS OF ALTERNATIVE STRATEGIES TO MANAGE PATIENTS WITH UNINVESTIGATED DYSPEPSIA: COMPARING THE CANDYS APPROACH TO ANTISECRETORY THERAPY AND PROMPT ENDOSCOPY American Journal of Gastroenterology. 98: S229. DOI: 10.1016/S0002-9270(03)01464-3 |
0.317 |
|
| 2001 |
Lachaine J, Laurier C, Manzi P. PID25: ECONOMIC EVALUATION OF MACROLIDES AND FLUOROQUINOLONES FOR THE TREATMENT OF RESPIRATORY TRACT INFECTIONS Value in Health. 4: 137-138. DOI: 10.1046/J.1524-4733.2001.40202-183.X |
0.34 |
|
| 2000 |
Lachaine J, Laurier C, Langleben A, Vaillant L. Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer. Critical Reviews in Oncology/Hematology. 32: 105-12. PMID 10612010 DOI: 10.1016/S1040-8428(99)00025-6 |
0.303 |
|
| 2000 |
Laurier C, Lachaine J, Manzi P. PHV5: EFFECTIVENESS AND COSTS OF ANTIBIOTICS IN THE AMBULATORY TREATMENT OF RESPIRATORY TRACT INFECTIONS Value in Health. 3: 118. DOI: 10.1016/S1098-3015(11)70497-1 |
0.304 |
|
| 1997 |
Laurier C, Kennedy W, Lachaine J, Gariepy L, Tessier G. Economic evaluation of zuclopenthixol acetate compared with injectable haloperidol in schizophrenic patients with acute psychosis. Clinical Therapeutics. 19: 316-29. PMID 9152570 DOI: 10.1016/S0149-2918(97)80120-8 |
0.355 |
|
| Show low-probability matches. |